CAR T-Cell Therapy

CAR T-cell therapy is a form of cancer immunotherapy in which T cells are genetically modified to express a synthetic receptor called a chimeric antigen receptor (CAR). This receptor enables the cells to recognize a selected antigen on a target cell and initiate an immune attack. Established treatments generally use the patient’s own cells and have approved applications in certain blood cancers. CAR T-cell therapy belongs to the broader category of adoptive cell therapy, in which immune cells are collected, manipulated, and administered as a treatment. (cancer.gov)

Biological principle

T cells are components of the immune system. Their natural T-cell receptors usually recognize antigen fragments presented by major histocompatibility complex molecules. A conventional CAR instead recognizes a target directly on the cell surface, without requiring this antigen-presentation pathway. Early experiments demonstrated that combining antibody recognition with T-cell receptor components could redirect T-cell specificity in this way. (pubmed.ncbi.nlm.nih.gov)

The receptor is chimeric because it combines components with different functions. Typical therapeutic designs include:

An extracellular binding region, commonly derived from an antibody, that recognizes the target.
A membrane-spanning region that anchors the receptor.
An intracellular activation region, commonly incorporating CD3ζ.
A costimulatory region, such as one derived from CD28 or 4-1BB, that supports cellular activation, expansion, and survival.

CARs combining an activation region with one costimulatory region are commonly called second-generation CARs. Receptor design influences how engineered cells respond and persist; receptors with different signaling components are not biologically interchangeable. (pmc.ncbi.nlm.nih.gov)

The introduced gene supplies instructions for making the receptor rather than directly killing the tumor. After target recognition, the engineered T cells carry out the immune response and can multiply inside the patient. This distinguishes CAR T-cell therapy from treatments consisting solely of an administered antibody or conventional drug. (fda.gov)

Production and treatment process

For an autologous product, the starting cells come from the person who will receive the treatment. The main stages are:

Collection: blood cells are collected by leukapheresis, a procedure that separates white blood cells from circulating blood.
Engineering: T cells are modified in a laboratory to introduce the CAR-encoding genetic material.
Expansion: the engineered cells are grown to produce the treatment dose.
Preparative treatment: a short course of lymphodepleting chemotherapy reduces other immune cells before administration.
Infusion and follow-up: the CAR T cells are delivered intravenously, followed by observation for treatment effects and complications. (ccr.cancer.gov)

Manufacturing is an individualized process and can take several weeks. Additional anticancer treatment may be used while the cells are being prepared. The interval between collection and infusion is clinically important because the underlying disease can progress during this period. (cancer.gov)

CAR T-cell therapy is distinct from hematopoietic stem-cell transplantation. Its administered cells are engineered immune effector cells, rather than stem cells intended to rebuild blood formation. Transplantation may nevertheless be part of a patient’s wider treatment history or subsequent care. (fda.gov)

Established clinical applications

The principal established targets are CD19, found on many normal and malignant B cells, and B-cell maturation antigen (BCMA), associated with plasma cells. These targets underpin treatments for selected forms of leukemia, lymphoma, and multiple myeloma. Approved indications differ between products and include restrictions concerning disease subtype, age, and previous treatment. (cancer.gov)

Examples include tisagenlecleucel, axicabtagene ciloleucel, brexucabtagene autoleucel, and lisocabtagene maraleucel for particular CD19-positive malignancies, and idecabtagene vicleucel and ciltacabtagene autoleucel for multiple myeloma. Obecabtagene autoleucel received US approval on November 8, 2024, for adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia. These are separate products, not interchangeable versions of a single treatment. (cancer.gov)

CAR T-cell therapy can produce durable remissions in some patients whose cancers have resisted earlier treatments. It does not work in every patient, and an initial complete remission does not necessarily mean permanent eradication of the disease. Some products have also moved into earlier treatment settings rather than being reserved exclusively for disease that has failed numerous previous therapies. (cancer.gov)

Adverse effects and long-term safety

CAR T-cell therapy can cause serious, sometimes fatal complications. Their frequency and severity vary by product, disease, and patient population. Major adverse effects include:

Cytokine release syndrome (CRS): a systemic inflammatory reaction associated with immune activation and release of cytokines. Manifestations can include fever, low blood pressure, oxygen deficiency, and organ dysfunction.
Immune effector cell-associated neurotoxicity syndrome (ICANS): neurological toxicity that may involve confusion, language disturbance, altered consciousness, or seizures.
Blood-cell suppression and infection: prolonged low blood-cell counts and impaired immune function can contribute to serious infections.
B-cell depletion and reduced antibody levels: CD19-targeted cells can attack normal B cells as well as malignant ones, producing B-cell aplasia and hypogammaglobulinemia. (fda.gov)

The loss of normal cells bearing the target illustrates on-target, off-tumor toxicity: recognition is molecularly correct, but the recognized antigen is not exclusive to cancer. This is an important constraint in selecting targets, especially when the antigen also occurs in essential healthy tissues. (ccr.cancer.gov)

In 2024, the US Food and Drug Administration required boxed warnings concerning secondary T-cell malignancies following CD19- or BCMA-directed autologous CAR T-cell therapies. Reported cases included tumors containing the CAR genetic sequence and fatal outcomes. Product labeling includes lifelong monitoring for secondary malignancies. These observations establish a safety concern but do not mean that every cancer arising after treatment was caused by the engineered cells. (fda.gov)

Limitations and research directions

Relapse can occur when tumor cells lose or reduce the targeted antigen, or when the engineered cells fail to remain sufficiently active. T-cell exhaustion, inadequate persistence, and the tumor’s capacity to suppress immune responses are additional obstacles. Investigational approaches include recognizing multiple targets and engineering cells whose activity can be regulated more precisely. (cancer.gov)

Solid tumors present further difficulties: suitable targets may also occur on healthy tissues, target expression may vary within a tumor, and local conditions can impede immune-cell activity. Research therefore includes altered receptor designs and cells engineered to carry additional immune-supporting signals. Results from laboratory and animal studies do not by themselves establish clinical safety or effectiveness. (cancer.gov)

Researchers are also investigating donor-derived, or allogeneic, CAR T cells to reduce dependence on individualized manufacturing. Such approaches must address immune compatibility and the possibility that the recipient will reject the administered cells. They remain distinct from the established autologous manufacturing model. (cancer.gov)

Beyond cancer, CD19-directed CAR T cells have been investigated in autoimmune diseases, including systemic lupus erythematosus, inflammatory myositis, and systemic sclerosis. A 2024 case series reported outcomes in 15 patients. Its small, uncontrolled design limits conclusions about comparative effectiveness, long-term safety, and which patients might benefit. (nejm.org)

Historical development

The scientific basis emerged from experiments redirecting T-cell recognition with synthetic receptors. A 1989 study demonstrated functional receptors combining antibody variable regions with T-cell receptor components. Subsequent development incorporated costimulatory signaling, improving the expansion and survival of engineered cells. (pubmed.ncbi.nlm.nih.gov)

A major regulatory milestone occurred on August 30, 2017, when the FDA approved tisagenlecleucel, marketed as Kymriah, for certain pediatric and young adult patients with B-cell acute lymphoblastic leukemia. This was the first FDA-approved CAR T-cell therapy and marked the transition of the approach from experimental treatment to licensed clinical use in the United States. (fda.gov)